Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
about
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionMaternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective studyHIV-1 Nef breaches placental barrier in rat modelImmune activation and paediatric HIV-1 disease outcomeThe Durban DeclarationReduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmissionEmergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmissionTime of HIV Diagnosis and Engagement in Prenatal Care Impact Virologic Outcomes of Pregnant Women with HIVChallenges in initiating antiretroviral therapy in 2010.The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?T cell virological synapses and HIV-1 pathogenesis.Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.Mobile phone text messages for improving adherence to antiretroviral therapy (ART): a protocol for an individual patient data meta-analysis of randomised trials.Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection.Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States.18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy.Frequent detection of escape from cytotoxic T-lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the ariel project for the prevention of transmission of HIV from mother to infant.Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.The second generation of HIV-1 vertically exposed infants: a case series from the Italian Register for paediatric HIV infectionAntiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998).Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.Biomedical prevention: state of the science.Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia.Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection.Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum.The ethics of anonymized HIV testing of pregnant women: a reappraisal.Interventions aimed at decreasing the risk of mother-to-child transmission of HIV infection.Women and HIV--revisited ten years on.Risk and management of blood-borne infections in health care workers.Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesHIV treatment as prevention: the key to an AIDS-free generation.Reducing mother-to-child transmission of HIV: findings from an early infant diagnosis program in south-south region of Nigeria.
P2860
Q24235500-6714BFBF-0E74-4FA5-9364-2622EB414BFEQ24243146-4A9086BC-143E-427D-BC0F-F0B0E49183A6Q24804378-B0473E2D-F058-4E5F-8932-FC9EAF9FBFF7Q27330468-19C5C3A6-84BC-4EB8-8F72-E83B6C899B39Q28086888-11CC2358-7240-4901-A3D8-748ABC63EDFCQ28140757-B2ADBB30-7F1F-4D75-A636-571CF14E8144Q28362322-E258E218-502D-4764-AE37-B796EF10C6A4Q28481233-36688CF2-28A3-41C1-B7C6-CCF955A13737Q28546081-546A30B5-3E95-4289-87ED-6B033A55EC48Q30227046-102B291D-FD32-4D40-9F41-738B022B9968Q30406147-23B9CE39-AD19-4456-AA67-D08432988FFEQ30415010-E78EC498-0E40-4869-A82F-6C3DDD2FAEEAQ30480959-3E086BF2-57CB-4903-9A6B-430973E0966CQ30651155-D98EF030-E952-453E-A1BC-D9768BD6B4D6Q30666487-29AC482A-CDD3-4BB0-B603-A5917FBD26B5Q30771786-A963A472-679B-4CEF-AB10-26CE81B6C6B0Q33320539-148E9FEE-AFF1-49B9-AA06-08298239DA37Q33441799-827AC3C6-B4F4-4F58-8133-560A2EEDB482Q33647187-FDCBD3BB-E38B-4EBB-AB03-DB89B9295947Q33668265-151223EA-35D0-4138-90EC-B227B2D87BB6Q33673661-57D1514D-96B7-4A66-BC46-ACE46509A2F4Q33700962-55045711-210E-4B94-B957-0E78B0F8D27FQ33711667-8669E7F1-B572-474E-8FEE-3E0A21A70C94Q33714594-AE5829D9-59AB-4F5D-AB21-0D1F0BFC18FCQ33765795-FE8A1801-0B32-4C73-95AE-B0F3BECD6421Q33772085-20449BD1-2D48-4985-8C55-4347F0A3B487Q33797464-E61F3E3B-F626-41AB-9AB8-C750C5186FCAQ33841004-39BE8A4D-B66A-47B7-921D-4B01B35E1679Q33850575-47500F88-90B4-4872-8B89-7CE5837A35FDQ33853585-5931925A-FC6F-4A57-AC6B-54BFEC0B8EDCQ33906773-693E22C5-B90D-4D0C-9794-2732D0828F10Q33926171-73A17648-A5D1-46A3-B41B-4848EB6023A8Q33961883-B7C9AE79-993E-4C82-BA18-455E5A40DF16Q34057304-5E921C21-4E34-44A7-83A1-4FC034BA1CF1Q34070706-F69B3EA6-B178-4D38-9E6B-C34F32281DE1Q34073785-85833F04-9586-446F-9FA0-365DE47E33B5Q34102747-014260F6-5E5D-4014-A2EF-D62D2C09C063Q34151052-FF690F2E-7777-46BE-98F8-3B9BAE0D4660Q34154129-FB5A55AA-2727-4746-ADD6-19A40A7B02A0Q34191977-D488F958-0686-4C53-B127-2E179044F850
P2860
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@ast
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@en
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@nl
type
label
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@ast
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@en
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@nl
prefLabel
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@ast
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@en
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@nl
P2093
P1476
Maternal viral load, zidovudin ...... roup Protocol 076 Study Group.
@en
P2093
McSherry GD
O'Sullivan MJ
Rouzioux C
Shapiro DE
Sperling RS
Sullivan JL
P304
P356
10.1056/NEJM199611283352201
P407
P577
1996-11-01T00:00:00Z